PEPTIDEAmericas
EN/ES
Back to resultsEspañol
Descriptive combination
Conceptual educational illustration of Modified GRF(1–29) / GRF modificado in a glass specimen jar, labelled MOLECULE PROFILE.

Modified GRF(1–29) / GRF modificado

View full illustrationSave Modified GRF(1–29) / GRF modificado

Conceptual educational illustration of Ipamorelin / Ipamorelina in a glass vial, labelled MOLECULE PROFILE.

Ipamorelin / Ipamorelina

View full illustrationSave Ipamorelin / Ipamorelina

COMBINATION PROFILE

CJC label + ipamorelin

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Components

Community claim

Growth-hormone release, recovery and body composition.

Community and market provenance

Community mention, not clinical evidence

  • Source: pdf01 · Page 2
  • Source: pdf04 · Page 5
  • Source: pdf05 · Page 2
  • Source: pdf06 · Page 2
  • Source: pdf06 · Page 6
  • Source: pdf07 · Page 1
  • Source: pdf09 · Page 2
  • Source: img01 · Page 1
  • Source: img03 · Page 1
  • Source: img04 · Page 1
  • Source: img07 · Page 1
  • Source: img09 · Page 1

Evidence of the exact combination

No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.

Component links are not combination evidence. A commercial name’s composition may vary.

Uncertainty and risks

DAC/no-DAC naming changes identity and exposure. Potential overlapping endocrine effects are mechanistic concerns, not a quantified interaction rate.

Observed in supplier/community material; prevalence not quantified.

No dosing or mixing instructions are provided.

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

  1. PMID16352683

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.

    DOI: 10.1210/jc.2005-1536PMID: 16352683

    October 16, 2026

  2. PMID25331030

    Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

    Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group.

    DOI: 10.1007/s00384-014-2030-8PMID: 25331030

    October 16, 2026

  3. R06

    FDA: current bulk-substance safety-risk page

  4. R10

    Teichman et al.: CJC-1295 human pharmacology, 2006

    DOI: 10.1210/jc.2005-1536PMID: 16352683
  5. R11

    CJC-1295 and preserved GH pulsatility, 2006

    DOI: 10.1210/jc.2006-1702PMID: 17018654
  6. R12

    Beck et al.: ipamorelin postoperative ileus trial, 2014

    DOI: 10.1007/s00384-014-2030-8PMID: 25331030
  7. pdf01

    PEPNEXA 2.pdf

    October 16, 2026

  8. pdf05

    PEPNEXA.pdf

    October 16, 2026

  9. pdf07

    US Peptide MangerCorp(1).pdf

    October 16, 2026

  10. pdf09

    PeptideFactory.pdf

    October 16, 2026

A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.